28 results on '"Arndt, Torsten"'
Search Results
2. Lessons learned from a case of tert-butyl glucuronide excretion in urine - "New" psychoactive alcohols knocking on the back door?
- Author
-
Arndt, Torsten, Stemmerich, Karsten, Buschmann, Hubert C., and Schulz, Katja
- Subjects
- *
ETHYL glucuronide , *BUTANOL , *URINALYSIS , *IMMUNOASSAY , *BIOMARKERS , *ETHANOL , *PSYCHIATRIC drugs - Abstract
Background: Ethyl glucuronide (EtG) in urine is considered a marker of recent ethanol consumption or ethanol exposition. tert-Butanol is primarily used as a solvent and intermediate chemical. Like tert-amyl alcohol, tert-butanol is discussed in Internet forums as ethanol replacement. We discuss false-positive immunological EtG screenings by excretion of different alcohol glucuronides (EtG homologs), mainly tert-butyl glucuronide in urine of a polytoxikomanic in-patient.Methods: Three consecutive urine samples from an in-patient with a long history of multiple substance abuse including solvents were analyzed by DRI EtG enzyme immunoassay (ThermoFisher Scientific Microgenics) on a Beckman Coulter AU680 analyzer, an in-house LC-MS/MS for EtG, 1-propyl, 2-propyl, 1-butyl, 2-butyl, and tert-butyl glucuronide, and an in-house headspace GC-FID of free congener substances methanol, 1-propanol, 2-butanone, 2-butanol, isobutanol, 1-butanol, 3-methyl-1-butanol, 2-methyl-1-butanol, and additionally for ethanol, acetone, 2-propanol, tert-butanol and 2-methyl-2-butanol.Results: EtG immunoassay yielded two positive urine samples (0.2 and 0.6mg/L or 0.1 and 0.2mg/g creatinine; cut-off 0.1mg/L) which were tested EtG negative by LC-MS/MS (cut-off 0.1mg/L) but positive for tert-butyl glucuronide (3.7 and 27.1mg/L), 2-butyl glucuronide (1.1 and 3.5mg/L), and 2-propyl glucuronide (0.1 and 0.4mg/L). Headspace GC-FID detected tert-butanol (0.97 and 4.01mg/L), methanol (0.96 and 0.62mg/L), 2-butanone (0.84 and 1.65mg/L), and 2-butanol (0.04 and 0.09mg/L), but no ethanol and no 2-methyl-2-butanol.Conclusion: Cross-reaction of EtG homologs, mainly tert-butyl glucuronide after suspected tert-butanol or isobutane abuse, explains the false-positive EtG immunoassay findings. Future investigations could address the usefulness of alcohol glucuronides (EtG homologs) in urine as (a) biomarkers of an exposition to alkans or their corresponding alcohol metabolites and (b) as markers for using "old"-well known alcohols like tert-butanol or tert-amyl alcohol as easy to obtain, cheap, potent and "undetectable" ethanol replacements or "New" Psychoactive Alcohols. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
3. Excessive urinary excretion of isopropyl glucuronide after isopropanol abuse.
- Author
-
Arndt, Torsten, Beyreiß, Reinhild, Hartmann, Werner, Schröfel, Stefanie, and Stemmerich, Karsten
- Subjects
- *
EXCRETION , *GLUCURONIDES , *BIOMARKERS , *ALCOHOL drinking , *MEDICAL screening - Abstract
Background: Ethyl glucuronide (EtG) in urine is considered a marker of alcohol consumption. We present a case of a false-positive immunological EtG screening result due to excessive isopropyl glucuronide excretion in urine of an alcohol-dependent patient with a history of industrial cleaning fluid abuse.Methods: EtG screening was done with the Microgenics DRI EtG enzyme immunoassay on a Beckman Coulter AU680 analyzer according to the testkit instructions. Confirmatory analysis was done by LC-MS/MS for EtG, 1-propyl (syn. n-propyl), 2-propyl (syn. isopropyl), 1-butyl, 2-butyl, and tert-butyl glucuronide. Both methods were validated according to the Guidelines of the Society of Toxicological and Forensic Chemistry (GTFCh, Germany).Results: EtG screening by immunoassay was positive, approx. 860mg/L or approx. 1540mg/g creatinine (forensic cut-off 0.1mg/L, clinical cut-off 0.5mg/L). LC-MS/MS confirmatory analysis was negative for EtG (<0.05mg/L; forensic cut-off 0.1mg/L), but strongly positive for 2-propyl glucuronide (approx. 1100mg/L or 2000mg/g creatinine; cut-off 0.1mg/L). 1-propyl, 1-butyl, and tert-butyl glucuronide were negative (<0.05mg/L; cut-off 0.1mg/L), 2-butyl glucuronide was 0.1mg/L (cut-off 0.1mg/L).Conclusion: Consumption of household and industrial chemicals with short chain aliphatic alcohols should be considered a rare but potential source of false-positive EtG immunoassay results. Glucuronides from frequently used short chain aliphatic alcohols, like 1-propanol (syn. n-propanol) and 2-propanol (syn. isopropanol) as the most important disinfectant components, should be included into EtG confirmatory analysis. This will be helpful not only for the assessment of the source for remarkable EtG immunoassay results, it can also contribute to a more specific diagnosis in cases with suspected intoxication by consumer or industrial chemical products. Excessive urinary 2-propyl glucuronide (syn. isopropyl glucuronide) concentrations should be considered a marker of isopropanol intoxication. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Über den Spessart hinaus von Bedeutung.
- Author
-
Arndt, Torsten
- Published
- 2022
5. Inhalation but not transdermal resorption of hand sanitizer ethanol causes positive ethyl glucuronide findings in urine.
- Author
-
Arndt, Torsten, Schröfel, Stefanie, Güssregen, Brunhilde, and Stemmerich, Karsten
- Subjects
- *
ALCOHOL , *ETHANOL , *HAND sanitizers , *URINE , *LIQUID chromatography-mass spectrometry - Abstract
Background: Ethyl glucuronide (EtG) in urine is considered a specific marker of recent ethanol consumption. There is an ongoing debate about whether inhalation or transdermal resorption of sanitizer ethanol is the underlying cause for positive EtG findings after hand disinfection. Methods: Desderman® pure (Schülake & Mary GmbH, Norderstedt) with 78.2 g 96% (v/v) ethanol/100 g and approx. 10% 2-propanol was used for multiple hand disinfection without and under an exhauster. Simulating a common working day in a clinic, 5 co-workers of our lab used the sanitizer 32 fold within 8 h and 2 persons were merely exposed to the sanitizer vapor but without any dermal sanitizer contact. Any additional ethanol intake or exposition was reliably excluded. Spot urine was collected at baseline, after 1, 2, 4, 6 . . . 14, and finally 24 h after the first sanitizer use. A validated LC-MS/MS was used forMRM and MS3 of EtG and qualitative analyses of ethyl sulfate and 2-propyl glucuronide. Results: Multiple hand disinfection caused positive EtG findings of up to 2.1 mg/L or 1.7 mg/g creatinine in 4 out of 5 test persons and even of 0.6 mg/L or 0.8 mg/g for 2 controls which were merely exposed to the sanitizer vapor but without any sanitizer contact. EtG results between the clinical (0.5 mg/g) and the forensic (0.1 mg/g) cut-off were obtained even 6 h after the last sanitizer exposition. An exhauster prevented the sanitizer vapor inhalation and reduced the EtG excretion to mostly below the detection limit of 0.02 mg/g. The maximum value was 0.09 mg/g. Ethyl sulfate and 2-propyl glucuronide (2-PpG) were detectable only in the EtG positive samples. 2-PpG is a metabolite of 2-propanol, which is quite frequently used in disinfectants. Thus, the detection of this substance can be used in cases of odd EtG results as an indicator of (unintended) sanitizer exposition. Conclusion: Ethanol from hand sanitizers is predominantly incorporated by the respiratory tract but not via the skin. It can cause a distinct ethyl glucuronide excretion and thus analytically true-positive but forensically false-positive EtG findings in the urine of ethanol abstaining persons. Since accidental ethanol inhalation can occur quite frequently in the working place or even private household, such a situation should always be considered when EtG is used as a marker of recent ethanol consumption. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Ethyl glucuronide identified in commercial hair tonics.
- Author
-
Arndt, Torsten, Schröfel, Stefanie, and Stemmerich, Karsten
- Subjects
- *
GLUCURONIDES , *ETHANOL , *DRUG use testing , *SUBSTANCE abuse , *DIETHYL sulfate , *FORENSIC sciences , *PHYSIOLOGY - Abstract
Background: Ethyl glucuronide (EtG) in hair is considered as a specific marker of ethanol consumption. Prompted by a report of positive EtG hair testings due to hair treatment with an EtG containing hair lotion, commercially available herbal hair tonics from supermarkets, drug-stores, and health food stores were analyzed for the presence of EtG and ethyl sulfate (EtS). Methods: LC-MS/MS (QTRAP 5500 mass spectrometer) was done in multiple reaction monitoring (MRM), enhanced product ion (EPI) and MS³ mode. The lower limit of quantitation was 0.05 mg/L for EtG and the cut-off for the detection of EtS 0.01 mg/L. Results: Altogether 11 hair tonics from 8 manufacturers were tested, with 1 product in 3 different lots. EtG ranged between 0.07 and 1.06 mg/L (7 products from 4 manufacturers) and was almost identical in the 3 lots of 1 product (1.01-1.06 mg/L). EtS was found in 3 out of the 11 hair tonics. Conclusions: EtG is quite frequently present in commercially available herbal hair tonics. Using EtG in hair as a marker of alcohol (ab)use, one has to consider external sources of EtG and has to assess the use of hair care products, esp. if the patient denies any ethanol intake. Whether EtS is a more reliable alcohol (ab)use marker, as sometimes discussed, should be critically assessed against the background of its broad use in large amounts in industrial chemistry. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer
- Author
-
Arndt, Torsten, Claussen, Ulrich, Güssregen, Brunhilde, Schröfel, Stefanie, Stürzer, Birgit, Werle, Annika, Wolf, Gerald, Güssregen, Brunhilde, Schröfel, Stefanie, and Stürzer, Birgit
- Subjects
- *
ALKALOIDS , *URINALYSIS , *TRAMADOL , *CLINICAL drug trials , *KRYPTON , *REHABILITATION , *DRUG addiction , *HERBAL medicine , *MIXTURES , *TANDEM mass spectrometry - Abstract
Abstract: Aim: A drug and alcohol withdrawal rehabilitation centre requested an analysis for “Krypton” in urine of a former opiate-addictive woman. She showed an altered clinical picture and behaviour with miosis, itchiness, agitation, and moderate euphoria after 3 months of until than successful treatment. Literature search revealed that “Krypton” is said to contain “Kratom” (leaves of Mitragyna speciosa), but could also contain O-desmethyltramadol (European Monitoring Centre for Drugs and Drug Addiction thematic paper “Spice”). Methods: Immunological drug screenings were done with test strips (nal von minden, Regensburg, Germany) and with cloned enzyme donor immunoassay (Microgenics, Passau, Germany). “Kratom” alkaloids and tramadol (metabolites) were analyzed by LC–MS/MS (ThermoFisher Scientific Quantum Ultra Triple Quadrupole mass spectrometer). Results: Immunoassays were negative for amphetamines, barbiturates, benzodiazepines, benzoylecgonine, buprenorphine, ethylglucuronide, methadone (metabolite), opiates, oxycodone, and THC-COOH, and test strips were negative for tramadol and its metabolites (cut-off 10mg/L for O-desmethyltramadol). LC–MS/MS detected the “Kratom” alkaloids mitragynine, speciociliatine, speciogynine, mitraciliatine, and paynantheine and approximately 9mg/L O-desmethyltramadol, but no tramadol and N-desmethyltramadol. Discussion: The detection of M. speciosa alkaloids is a proof of “Kratom” abuse. Confronted with the analysis data, the patient admitted to have consumed 3–4 infusions of “Krypton”. The origin of the O-desmethyltramadol is unclear. Tramadol abuse is unlikely since tramadol and N-desmethyltramadol (physiologically occurring in urine after tramadol intake) were not detectable. Consumption of a “Krypton” product spiked with O-desmethyltramadol could explain our findings and the patient''s clinical picture. This would be in agreement with a most recent report about spiking apparently natural herbal mixtures with the synthetic opioid O-desmethyltramadol. Conclusion: Analysis of “Kratom” abuse should not be restricted to M. speciosa alkaloids, but should also consider synthetic drugs which could be added to the herbal mixtures. Mass spectrometry based drug screenings will gain importance to keep pace with the dynamic drug market. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
8. Atypical serum transferrin isoform distribution in liver cirrhosis studied by HPLC, capillary electrophoresis and transferrin genotyping
- Author
-
Arndt, Torsten, van der Meijden, Brenda B., and Wielders, Jos P.M.
- Subjects
- *
IRON in the body , *CARRIER proteins , *BLOOD proteins , *PHASE partition - Abstract
Abstract: Background: An incomplete separation of disialotransferrin (CDT) and trisialotransferrin (a non-CDT isoform) may cause false-positive CDT results in alcohol abuse testing. We describe a currently unknown disialotransferrin-trisialotransferrin-bridging phenomenon (di-tri-bridge) appearing with high prevalence in serum from liver cirrhosis patients. Methods: Twenty one consecutive serum samples with a di-tri-bridge encountered in routine CDT HPLC (Clin-Rep®-CDT-on-line, Recipe) were investigated by a candidate reference CDT HPLC method, by capillary electrophoresis (Capillarys-CDT, Sebia) and by transferrin genotyping. Patients clinical background was assessed by telephone interview. Results: Out of 21 consecutive serum samples showing a di-tri-bridge (and increased trisialotransferrin fractions) in HPLC as well as in CE analysis, 19 were from patients with a liver cirrhosis history. Genotyping (where applicable by the availability of DNA: n =12) yielded most frequently homozygous transferrin C1 (6x), proving that the di-tri-bridge cannot be explained by genetic transferrin variants in these samples. Other genotypes found were C2 (1x), C1C2 (4x), C1C3 (1x). Conclusion: The frequently seen di-tri-bridging phenomenon in transferrin HPLC analysis for patients with liver cirrhosis is not explained by genetic transferrin variants or by an increased trisialotransferrin fraction. Although further studies are needed to assess the relationship between this phenomenon and liver cirrhosis, our observation could be helpful in development of a biomarker for liver cirrhosis. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
9. Forensic analysis of carbohydrate-deficient transferrin (CDT) by HPLC—Statistics and extreme CDT values
- Author
-
Arndt, Torsten, Guessregen, Brunhilde, Hallermann, Dörte, Nauck, Markus, Terjung, Dirk, and Weckesser, Holger
- Subjects
- *
ORGANIC compounds , *ALCOHOL drinking , *FORENSIC sciences , *CRIMINAL investigation - Abstract
Abstract: Background: Carbohydrate-deficient transferrin (CDT) is the most specific serum marker of chronic alcohol abuse so far. There is little knowledge about extreme CDT values of >20% and the more >30% CDT. Methods: Serum CDT/transferrin ratios from 19,236 serum samples sent to our laboratory for routine CDT analysis were determined by HPLC. About 75% of these serum samples were from traffic or employment medicine investigations. A CDT value frequency histogram was computed and extreme CDT values were clinically validated. Results: Fourteen thousand four hundred and sixty-one CDT results were normal (≤1.7%) and 4775 increased (1.8–36.9% CDT). Most frequent normal and increased results were 0.9% CDT (n =1964) and 1.8% CDT (n =356). CA. 70% of the pathological results were between 1.8% and 5.0% CDT, ca. 88% between 1.8% and 10.0% CDT, and 98% between 1.8% and 20.0%. CDT values >20.0% appeared in 79 cases and results >30.0% in two cases (33.8% and 36.9%). In each case of CDT values >20%, chronic alcohol abuse was the underlying cause as confirmed by anamnestic exploration. Conclusions: CDT/transferrin ratios are usually <20%. Higher values can appear in rare cases. CDT results >30% can be due to alcohol abuse but should be considered as remarkable single observations. Visualization of the transferrin isoform patterns by HPLC allows the detection of pathological transferrin isoform patterns and of genetic transferrin variants. This is essential for a reliable interpretation of (extreme) CDT values. CDT analysis by immunoassays without physico-chemical confirmatory analysis is no longer acceptable. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
10. Synthesis of angularly fused cyclopentanoids and analogous tricycles via photoinduced ketyl radical/radical anion fragmentation–cyclization reactions
- Author
-
Tzvetkov, Nikolay T., Arndt, Torsten, and Mattay, Jochen
- Subjects
- *
ANIONS , *FRAGMENTATION reactions , *RING formation (Chemistry) , *CHARGE exchange - Abstract
Abstract: Angular fused tricycles were synthesized through intramolecular tandem fragmentation–cyclization reactions by photochemically induced electron transfer (PET) of tricyclic α-cyclopropyl ketones with an unsaturated side chain at the position γ to the carbonyl group. The reactions resulted in regioselective cleavage of a β-cyclopropyl bond with formation of angular fused tricyclic ring systems via ketyl radical/radical anions as reactive intermediates. In general, triethylamine (TEA) was used as a strong reducing reagent in acetonitrile. The preferred regioselectivity of the cyclization step (exo vs endo) depending on the substitution pattern at the quaternary carbon center (Cβ′) of the tricyclic α-cyclopropyl ketones was investigated. In addition, we also checked a two-step pathway for the synthesis of angular dioxa-triquinanes including photolysis of an allyloxy-substituted cyclopenta[c]furanone derivative and subsequent β-cleavage of the resulted dioxa-[4.5.5.5]fenestrane under reductive PET conditions. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
11. High prevalence of increased trisialotransferrin concentrations in patients with anorexia nervosa: Implications for determination of carbohydrate-deficient transferrin
- Author
-
Arndt, Torsten, Erkens, Manfred, Holtkamp, Kristian, Keller, Thomas, and Gressner, Axel M.
- Subjects
- *
ANOREXIA nervosa , *TRANSFERRIN , *EATING disorders , *GEL electrophoresis - Abstract
Abstract: Background: Carbohydrate-deficient transferrin (asialo-+monosialo-+disialotransferrin, CDT) is currently the most specific laboratory marker of chronic alcohol abuse. We tested whether previous findings of false-positive CDT results for anorexia nervosa patients have been due to invalid CDT analysis methods or anorexia nervosa by itself. Methods: Serum CDT from 49 anorexia nervosa patients, 14 bulimia nervosa patients and 22 healthy controls (all adolescent, female and age-matched) was determined in a retrospective study by HPLC (Clin-Rep®-CDT-in-serum-online, cut-off ≥1.8%, Recipe), by capillary electrophoresis (Capillarys-CDT, cut-off ≥1.3%, Sebia) and (due to limited surplus serum volume for a subset of 18 anorexia nervosa patients with increased trisialotransferrin detected by HPLC) by immunoassay based on anion-exchange CDT and non-CDT fractionation (%CDT-TIA, cut-off ≥2.6% CDT, Bio-Rad). Results: HPLC and capillary electrophoresis: No false-positive CDT results were obtained. Asialo- and monosialotransferrin were not detected and disialotransferrin (CDT) was in each case clearly below the test-specific cut-offs. Trisialotransferrin (a non-CDT isoform) was increased (cut-off ≥5.0% for HPLC) in 33 anorexia patients, 2 bulimia patients and 2 controls. %CDT-TIA: 8 false-positive CDT results of ≥2.6% out of the 18 samples tested (CDT-range/mean/median 2.6–4.6/3.2/2.8%). Conclusions: Anorexia nervosa does not cause by itself increased CDT results. False-positive CDT values from the past are most likely due to an incomplete separation of trisialotransferrin from CDT and thus overdetermination of CDT. Immunological CDT testing without confirmatory analysis by HPLC or CE is no longer acceptable. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
12. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method.
- Author
-
Jeppsson, Jan-Olof, Arndt, Torsten, Schellenberg, François, Wielders, Jos P. M., Anton, Raymond F., Whitfield, John B., and Helander, Anders
- Subjects
- *
TRANSFERRIN , *BLOOD proteins , *IRON proteins , *BIOMARKERS , *ALCOHOL drinking , *STANDARDIZATION , *CLINICAL chemistry - Abstract
An alcohol-associated change in the serum transferrin glycoform pattern, carbohydrate-deficient transferrin (CDT), is used as a biomarker of chronic moderate to heavy alcohol consumption. A current limitation in CDT analysis is the lack of standardization, which hampers clinical and analytical comparison between studies. This situation prompted initiation of a Working Group (WG) on CDT Standardization under the auspices of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). The standardization work aims to define and validate the analyte, select a reference method, work out procedures for the production of reference materials, and make suggestions for the clinical usage of CDT. The first recommendation of the WG is that disialotransferrin should be the primary target molecule for CDT measurement and the single analyte on which CDT standardization is based. It is further recommended that HPLC should be the analytical principle considered as the basis of an interim reference method until a suitable mass spectrometric reference method is established. In clinical use, CDT should be expressed in a relative amount (% CDT), to compensate for variations in the total transferrin concentration. Clin Chem Lab Med 2007;45:558–62. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Argininosuccinate lyase deficiency (ASL) and carbohydrate-deficient transferrin (CDT): Experience with four independent CDT analysis methods — misleading results given by the %CDT TIA assay
- Author
-
Arndt, Torsten, Gressner, Axel, Herwig, Jürgen, Meier, Ursula, and Sewell, Adrian C.
- Subjects
- *
TRANSFERRIN , *CARRIER proteins , *IMMUNOGLOBULINS , *BLOOD plasma - Abstract
Abstract: Background: Chronic liver disease can cause false-positive carbohydrate-deficient transferrin (CDT) results mimicking chronic alcohol abuse. We tested whether argininosuccinate lyase deficiency (ASL), a genetic disorder of the urea cycle with hepatomegaly and biochemical hepatitis, causes increased CDT results and whether this depends on the analytical method. Methods: Seven serum samples from four ASL patients without alcohol abuse were analyzed by capillary electrophoresis, HPLC, particle-enhanced immunonephelometry with monoclonal CDT antibodies, and microcolumn CDT and non-CDT fractionation followed by a turbidimetric immunoassay with transferrin antibodies (%CDT TIA). Results: Increased CDT results (two out of four patients or five out of seven samples) were obtained by the %CDT TIA assay, but not by the remaining three CDT tests. The corresponding serum samples showed increased fractions of trisialotransferrin by HPLC (as the IFCC reference method for CDT analysis). One sample contained an elevated trisialotransferrin but a normal CDT also in the %CDT TIA test. One patient had a normal trisialotransferrin and a normal CDT as assayed by each of the four CDT methods. Conclusions: Argininosuccinate lyase deficiency is not itself a cause for increased CDT values. Increased fractions of trisialotransferrin in ASL patients appear to interfere with CDT analysis by the %CDT TIA assay. This can give false-positive CDT results. Since this can appear not only in ASL patients, microcolumn CDT and non-CDT fractionation followed by a turbidimetric immunoassay using transferrin but not CDT antibodies by the %CDT TIA assay should no longer be used for CDT measurement without confirmatory analysis by HPLC or capillary electrophoresis. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
14. Primary biliary cirrhosis is not a clinical condition for increased carbohydrate-deficient transferrin: Experience with four independent CDT analysis methods
- Author
-
Arndt, Torsten, Meier, Ursula, Nauck, Markus, and Gressner, Axel M.
- Subjects
- *
CIRRHOSIS of the liver , *TRANSFERRIN , *CARBOHYDRATE metabolism , *ELECTROPHORESIS - Abstract
Abstract: Background: Primary biliary cirrhosis (PBC) is considered as an important cause for increased carbohydrate-deficient transferrin (CDT). The underlying pathomechanism is difficult to explain by the pathogenesis and/or consequences of PBC. We tested whether PBC causes increased CDT results with current CDT analysis methods and, if so, whether this depends on the CDT analysis principle. Methods: 48 serum samples from PBC patients were analyzed by HPLC, microcolumn CDT and non-CDT fractionation followed by a turbidimetric immunoassay, particle-enhanced immunonephelometry with monoclonal CDT antibodies, and capillary electrophoresis. The test-specific decision limits were used for categorization of the CDT analysis results into normal and increased values. Results: HPLC: 47 normal/1 increased, microcolumn+TIA: 46 normal/2 increased, particle-enhanced immunonephelometry: 41 normal/7 increased, capillary electrophoresis: 48 normal CDT results. After combining an immunological CDT test (microcolumn+TIA or particle-enhanced immunonephelometry) as the screening method with a physico-chemical CDT test (HPLC or electrophoresis) as the confirmatory method, 1 case remained with increased CDT values by the screening (value 2.6%, cut-off 2.5%, particle-enhanced immunonephelometry) and confirmatory (value 1.8%, cut-off 1.75%, HPLC) analysis. Conclusions: PBC should no longer be overstressed as an important cause for false-positive CDT results regarding chronic alcohol abuse. In the presence of odd CDT results, PBC should be considered in the anamnestic exploration. However, PBC is not by itself a cause for increased CDT values. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
15. Determination of serum amantadine by liquid chromatography-tandem mass spectrometry
- Author
-
Arndt, Torsten, Guessregen, Brunhilde, Hohl, Axel, and Reis, Janine
- Subjects
- *
SEPARATION (Technology) , *HIGH performance liquid chromatography , *VIRUS diseases , *MASS spectrometry - Abstract
Abstract: Background: Amantadine (1-adamantylamine) is used for treatment of influenza, hepatitis C, parkinsonism, and multiple sclerosis. Current amantadine analysis by HPLC or gas chromatography (GC) requires a laborious sample pretreatment with extraction and/or derivatization steps. We established an LC-MS/MS method without protein precipitation, centrifugation, extraction and derivatization steps. Material and methods: 50 μl sample+50 μl of 0.4 mg/l 1-(1-adamantyl)pyridinium bromide as internal standard+1000 μl water (96-well plate). Of this 25 μl+500 μl water (96-well plate; final serum dilution 1:462). LC-MS/MS: Surveyor MS pump, Autosampler, triple-quadrupole TSQ Quantum mass spectrometer (Thermo Electron). Autosampling: 2 μl of each sample. Chromatography: isocratic water/acetonitrile (60/40 v/v) with 5 g/l formic acid, flow rate 0.2 ml/min, run time 3 min, Phenomenex Luna C8(2) (100×2.0 mm (i.d.); 3-μm bead size) column. Mass spectrometry: electrospray atmospheric pressure ionization, positive ion and selective reaction monitoring mode, ion transitions m/z 152.0→135.1 (at 22 eV amantadine) and 214.1→135.1 (at 26 eV internal standard). Results: Calibration curves were constructed with spiked serum samples (amantadine 50–1000 μg/l, r >0.99). No carry over (5000 μg/l). No ion suppression with retention times similar to those of amantadine (1.8 min) and the internal standard (2.1 min). Detection limit 20 mg/l, linearity 20–5000 mg/l, intra-assay/inter-assay CV<6%/<8%, recovery 99–101%. Method comparison: LC-MS/MS=1.23×GC-45 (Passing-Bablok regression). No significant bias between GC and LC-MS/MS (Bland-Altman plot). Conclusion: We consider the sample pretreatment without deproteination, derivatization and centrifugation steps and the specificity of the tandem mass spectrometry as the most important points of our amantadine analysis method. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
16. Forensic analysis of carbohydrate-deficient transferrin (CDT): implementation of a screening and confirmatory analysis concept is hampered by the lack of CDT isoform standards
- Author
-
Arndt, Torsten and Keller, Thomas
- Subjects
- *
TRANSFERRIN , *CARBOHYDRATES , *IMMUNOASSAY , *ANALYSIS of variance - Abstract
The aim of the study was to test combinations of commercially available carbohydrate-deficient transferrin (CDT) assays for their usefulness as screening and confirmatory CDT analysis systems. A set of 292 serum samples from routine CDT analysis was analyzed by two assays based on anion-exchanger microcolumn CDT and non-CDT fractionation followed by a turbidimetric immunoassay (ChronAlcoI.D. and %CDT TIA) and a high-performance liquid chromatography with on-line sample preparation (ClinRep CDT on-line). The CDT analysis results were divided into four groups based on the test-specific borderlines of the compared methods: NN with negative CDT results by both tests, PN with positive screening but negative confirmation results, NP with negative screening and positive confirmation results, and PP with positive results by both tests. Regardless of the test combination and whether applying the lower or upper limits of the borderlines, approximately one-third of contradictory (positive screening and negative confirmation or vice versa corresponding to groups PN and NP) were obtained. This was not due to analytical outliers (only 6 of 292 serum samples). Indeed, parametric and non-parametric ANOVA analysis pointed to different calibrations and/or recoveries of the three CDT assays. Our data give again evidence for the urgent need of an international CDT isoform standard material. At this time, we cannot recommend a combination of the three tests for screening and confirmatory analysis in forensic CDT testing. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
17. CDTect-RIA and CDTect-EIA for determination of serum carbohydrate-deficient transferrin compared.
- Author
-
Arndt, Torsten, Kropf, Juergen, Brandt, Ragnhild, Gressner, Axel M., Hackler, Rolf, Herold, Manfred, Van Pelt, Johannes, Mårtensson, Ola, Salzmann, Karin, and Velmans, Mathieu H.
- Subjects
- *
SERUM , *TRANSFERRIN , *RADIOIMMUNOASSAY , *ENZYME-linked immunosorbent assay , *LABORATORIES - Abstract
CDTect-RIA and CDTect-EIA for determination of serum carbohydrate-deficient transferrin (CDT) by radioimmunossay and enzyme immunoassay respectively were tested for equality and precision in four European laboratories. For correlational studies, serum samples with CDT concentrations up to 130 U/I were analysed in accordance with a uniform trial schedule. The regression of CDT values obtained by the two procedures was computed for each laboratory using the method of Passing and Bablok. Slopes and intercepts of the regression functions did not differ significantly from the values 1 or 0, as proved by the corresponding 95% confidence intervals. Precision studies were computed using analysis of variance. For CDT concentrations at the upper reference limit for men, the within-day coefficients of variation (CVs) ranged between 0.7 and 6.4% (median 5.2%) for CDTect-RIA and from 4.3 to 9.2% (median 6.2%) for CDTect-EIA. The corresponding pure between-day CVs were 5.0-18.5% (median 9.8%) and 3.5-14.5% (median 10.9%). The study demonstrates the equality of CDT values obtained by CDTect-RIA and CDTect-EIA. According to this study, the two methods can be used interchangeably without getting fluctuating CDT values, e.g. in longitudinal studies. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
18. Rapid communication. Carbohydrate-deficient transferrin is not affected by serum separators.
- Author
-
ARNDT, TORSTEN, CZYLWIK, DIETRICH, HACKLER, ROLF, HELWIG-ROLIG, ANGELIKA, and GILG, THOMAS
- Subjects
- *
TRANSFERRIN , *SERUM , *BLOOD collection , *ACRYLAMIDE , *NEURAL tube - Abstract
We studied the possible effects on serum carbohydrate-deficient transferrin (CDT) determination by a CDTect (Pharmacia) method of serum isolation in four different types of blood-collection tubes, namely: (1) glass tubes (glass Vacutainer tubes with no additive); (2) S-Monovette Neutral tubes (plastic tubes with no additive); (3) S-Monovette Serum tubes (plastic tubes with kaolin-coated plastic granulate coagulation accelerator); and (4) S-Monovette Serum/Gel tubes (plastic tubes with kaolin-coated plastic granulated and a polymerized acrylamide resin). Using Passing and Bablok regression analysis, we did not observe significant differences in CDT concentrations determined in 58 serum samples using any of these four blood-collection systems. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
19. Cross-reaction of propyl and butyl alcohol glucuronides with an ethyl glucuronide enzyme immunoassay.
- Author
-
Arndt, Torsten, Beyreiß, Reinhild, Schröfel, Stefanie, and Stemmerich, Karsten
- Subjects
- *
BUTANOL , *GLUCURONIDES , *ENZYME-linked immunosorbent assay , *BIOMARKERS , *CONFIRMATORY factor analysis , *BIOLOGICAL assay - Abstract
Background: Ethyl glucuronide (EtG) in urine is considered a marker of recent alcohol consumption. Using immunoassays for EtG screening without confirmatory analysis bears a risk of getting false-positives as shown for trichloroethyl glucuronide from chloral hydrate medication and 1-propyl glucuronide from propanol-based hand disinfection. The aim of the study was to check whether glucuronides of frequently used aliphatic short chain alcohols aside from EtG and 1-propyl glucuronide can cross-react with the DRI1 Ethyl Glucuronide Assay. Methods: Aliquots of EtG-free urine were individually spiked with methyl β-D-glucuronide, 1-propyl β-Dglucuronide, 2-propyl β-D-glucuronide, 1-butyl β-D-glucuronide, 2-butyl β-D-glucuronide, and tertbutyl β-D-glucuronide. To check the response rate of the DRI1 Ethyl Glucuronide Assay to its target analyte, EtG was also added to a native EtG-free urine sample. The spiked alcohol glucuronide concentrations (seven levels up to 10 mg/L) and the DRI1 Ethyl Glucuronide Assay results were evaluated by Passing-Bablok regression analysis. The 95% confidence interval ranges for the slope of the regression function were considered a measure of cross-reaction of the individual alcohol glucuronides with the enzyme immunoassay. Results: 2-Propyl glucuronide showed a cross-reactivity of 69-84% at the 95% probability level, methyl glucuronide, 1-propyl glucuronide, and 1- and 2-butyl glucuronide of 4-9%, and tert-butyl glucuronide almost no cross-reactivity. The response rate for EtG was 87-94% at the 95% probability level. Conclusion: The DRI1 Ethyl Glucuronide Assay shows cross-reaction rates with aliphatic short chain alcohol glucuronides aside from EtG which bear a risk of getting false-positives regarding ethanol consumption. Mass spectrometric detection of EtG is mandatory for confirmation of positive immunological EtG screenings. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Standardization of carbohydrate-deficient transferrin: reply to the letter by Tagliaro and Bortolotti.
- Author
-
Jeppsson, Jan-Olof, Arndt, Torsten, Schellenberg, François, Wielders, Jos P. M., Anton, Raymond F., Whitfield, John B., and Helander, Anders
- Subjects
- *
LETTERS to the editor , *TRANSFERRIN - Abstract
A letter to the editor is presented in response to the article on standardization of carbohydrate-deficient transferrin that was published in the previous issue.
- Published
- 2008
- Full Text
- View/download PDF
21. Carbohydrate-deficient transferrin and anorexia nervosa
- Author
-
Arndt, Torsten and Keller, Thomas
- Published
- 2006
- Full Text
- View/download PDF
22. Valid carbohydrate-deficient transferrin testing
- Author
-
Arndt, Torsten
- Published
- 2006
- Full Text
- View/download PDF
23. False-positive ethyl glucuronide immunoassay screening associated with chloral hydrate medication as confirmed by LC–MS/MS and self-medication
- Author
-
Arndt, Torsten, Gierten, Birgit, Güssregen, Brunhilde, Werle, Annika, and Grüner, Joachim
- Subjects
- *
IMMUNOASSAY , *GLUCURONIDES , *CHLORAL , *LIQUID chromatography , *MASS spectrometry , *SELF medication , *URINALYSIS , *IMMUNODIAGNOSIS - Abstract
Abstract: Background: Urine-ethyl glucuronide (EtG) concentrations are considered as a specific marker of recent alcohol consumption. We describe false-positive EtG screening results by the DRI® ethyl glucuronide enzyme immunoassay caused by chloral hydrate intake. Methods: Urine-EtG-screening: DRI® EtG enzyme immunoassay (Thermo Fisher Scientific Microgenics) on a Hitachi 912 analyzer. EtG- and ethyl sulfate (EtS) confirmatory analysis: LC–MS/MS with an ESI source in the negative ionization, selective reaction monitoring mode. Patient: ethanol-abstaining women under buprenorphine-treatment (medication with levetiracetam, gabapentin, clomethiazol and chloral hydrate). Proband: self-medication with 500mg chloral hydrate after a 5-day ethanol abstinence. EtG analysis for both in subsequent urines. Check for cross reactions of the pharmaceuticals with the EtG immunoassay by addition of pure substance (2g/L each) to EtG-free urine. Results: EtG concentrations up to 8.0mg/L or 7.0mg/g creatinine (cut-off 0.5mg/L or mg/g) for the patient and up to 0.28mg/L or 0.35mg/g for the control subject (after 500mg chloral hydrate) were obtained by the immunoassay. LC–MS/MS could not confirm these EtG results. In fact, EtG and/or EtS were not detectable in any of the urine samples by LC–MS/MS (lower limit of detection 0.01mg/L). Cross reactions of the pharmaceuticals, incl. the chloral hydrate metabolites trichloroethanol and trichloroacetic acid, with the DRI® EtG immunoassay results were ruled out (by spiking experiments) as the underlying cause for the false-positive EtG immunoassay results. Conclusions: Trichloroethyl glucuronide as an important chloral hydrate metabolite remains the most probable cross reacting substance with the DRI® EtG immunoassay (unproven because of lack in pure standard). The chloral hydrate self-medication experiment clearly points to an association of the false-positive EtG immunoassay results and chloral hydrate intake. Chloral hydrate medication has to be considered as a cause for false-positive EtG screening results by the DRI® EtG immunoassay even in cases with regular chloral hydrate treatment (250–1000mg) and the more in patients with chloral hydrate tolerance (taking g/day). It is recommended that positive EtG immunoassay results always be confirmed by a more specific technique such as LC–MS/MS, including ethyl sulfate as a second minor ethanol metabolite. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
24. Reprint of Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT).
- Author
-
Helander, Anders, Wielders, Jos, Anton, Raymond, Arndt, Torsten, Bianchi, Vincenza, Deenmamode, Jean, Jeppsson, Jan-Olof, Whitfield, John B., Weykamp, Cas, and Schellenberg, François
- Subjects
- *
CARBOHYDRATES , *TRANSFERRIN , *BLOOD serum analysis , *ALCOHOL drinking , *REFERENCE sources - Abstract
Carbohydrate-deficient transferrin (CDT) is a glycoform profile of serum transferrin that increases in response to sustained high alcohol intake and over the last decades has become an important alcohol biomarker with clinical and forensic applications. However, the wide range of CDT measurement procedures has resulted in lack of uniform results and reference limits, and hampered comparison of results. In 2005, the IFCC therefore founded a special working group (WG) aiming for standardisation of CDT measurement. This review summarises the history of CDT and the actions taken by the WG-CDT. Initial steps included the definition of the measurand (serum disialotransferrin to total transferrin fraction expressed in %), and the determination of a well-defined anion-exchange HPLC procedure as the candidate reference measurement procedure (cRMP). Subsequent achievements were the establishment of a network of reference laboratories to perform the cRMP, setting a reference interval, and development of a reference material based on human serum for which the laboratory network assign values. Using a set of reference materials for calibration allowed for achieving equivalence of results of all present CDT measurement procedures. The final steps of the WG-CDT have been a full validation of the cRMP to make it an IFCC approved RMP, and providing guidance for international standardisation of all CDT measurement procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT).
- Author
-
Helander, Anders, Wielders, Jos, Anton, Raymond, Arndt, Torsten, Bianchi, Vincenza, Deenmamode, Jean, Jeppsson, Jan-Olof, Whitfield, John B., Weykamp, Cas, and Schellenberg, François
- Subjects
- *
BIOMARKERS , *CARBOHYDRATES , *TRANSFERRIN , *ALCOHOLISM , *BLOOD proteins - Abstract
Carbohydrate-deficient transferrin (CDT) is a glycoform profile of serum transferrin that increases in response to sustained high alcohol intake and over the last decades has become an important alcohol biomarker with clinical and forensic applications. However, the wide range of CDT measurement procedures has resulted in lack of uniform results and reference limits, and hampered comparison of results. In 2005, the IFCC therefore founded a special working group (WG) aiming for standardisation of CDT measurement. This review summarises the history of CDT and the actions taken by the WG-CDT. Initial steps included the definition of the measurand (serum disialotransferrin to total transferrin fraction expressed in %), and the determination of a well-defined anion-exchange HPLC procedure as the candidate reference measurement procedure (cRMP). Subsequent achievements were the establishment of a network of reference laboratories to perform the cRMP, setting a reference interval, and development of a reference material based on human serum for which the laboratory network assign values. Using a set of reference materials for calibration allowed for achieving equivalence of results of all present CDT measurement procedures. The final steps of the WG-CDT have been a full validation of the cRMP to make it an IFCC approved RMP, and providing guidance for international standardisation of all CDT measurement procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Functional genomics of pain in analgesic drug development and therapy.
- Author
-
Lötsch, Jörn, Doehring, Alexandra, Mogil, Jeffrey S., Arndt, Torsten, Geisslinger, Gerd, and Ultsch, Alfred
- Subjects
- *
FUNCTIONAL genomics , *PAIN management , *ANALGESICS , *DRUG development , *DRUG therapy , *G protein coupled receptors , *CELLULAR signal transduction - Abstract
Abstract: Advances in genomic research have led to the clarification of the detailed involvement of gene products in biological pathways and these are being increasingly exploited in strategies for drug discovery and repurposing. Concomitant developments in informatics have resulted in the acquisition of complex gene information through the application of computational analysis of molecular interaction networks. This approach enables the acquired knowledge on hundreds of genes to be used to view molecular disease mechanisms from a genetic point of view. By analyzing 410 genes which control the complex process of pain, we show by computational analysis, based on functional annotations to pain-related genes, that 12 clearly circumscribed functional areas are essential for pain perception and thus for analgesic drug development. The genetics perspective revealed that future development strategies should focus on substances modulating intracellular signal transduction, ion transport and anatomical structure development. These processes are involved in the genetic-based absence of pain and therefore, provide promising fields for curative or preventive treatments. In contrast, interactions with G-protein coupled receptor pathways seem merely to provide symptomatic, not preventative relief of pain. In addition, biological functions accessed either by analgesic drugs or microRNAs suggest that synergistic therapies may be a future direction for drug development. With modern computational functional genomics, it is possible to exploit genetic information from increasingly available data sets on complex diseases, such as pain, and offers a new insight into drug development and therapy which is complementary to pathway-centered approaches. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
27. Modulation of Human Motor Cortex Excitability by Single Doses of Amantadine.
- Author
-
Reis, Janine, John, Daniel, Heimeroth, Antje, Mueller, Hans-Helge, Oertel, Wolfgang H., Arndt, Torsten, and Rosenow, Felix
- Subjects
- *
AMANTADINE , *PARKINSON'S disease , *AMINES , *ANTIPARKINSONIAN agents , *ANTIVIRAL agents - Abstract
Amantadine-sulfate has been used for several decades to treat acute influenza A, Parkinson's disease (PD), and acute or chronic drug-induced dyskinesia. Several mechanisms of actions detected in vivo/in vitro including N-methyl-D-aspartate (NMDA)-receptor antagonism, blockage of potassium channels, dopamine receptor agonism, enhancement of noradrenergic release, and anticholinergic effects have been described. We used transcranial magnetic stimulation (TMS) to evaluate the effect of single doses of amantadine on human motor cortex excitability in normal subjects. Using a double-blind, placebo-controlled, crossover study design, motor thresholds, recruitment curves, cortical stimulation-induced silent period (CSP), short intracortical inhibition (ICI), intracortical facilitation (ICF), and late inhibition (L-ICI) in 14 healthy subjects were investigated after oral doses of 50 and 100 mg amantadine with single and paired pulse TMS paradigms. Spinal cord excitability was investigated by distal latencies and M-amplitudes of the abductor digiti minimi muscle. After intake of amantadine, a significant dose-dependent decrease of ICF was noticed as well as a significant increase of L-ICI as compared to placebo. The effect on ICF and L-ICI significantly correlated with amantadine serum levels. ICI was slightly increased after amantadine intake, but the effect failed to be significant. Furthermore, amantadine had no significant effects on motor thresholds, MEP recruitment curves, CSP, or peripheral excitability. In conclusion, a low dose of amantadine is sufficient in modulating human motor cortex excitability. The decrease of ICF and increase of L-ICI may reflect glutamatergic modulation or a polysynaptic interaction of glutamatergic and GABA-ergic circuits. Although amantadine has several mechanisms of action, the NMDA-receptor antagonism seems to be the most relevant effect on cortical excitability. As L-ICI can be influenced by this type of drug, it may be an interesting parameter for studies of motor learning and use-dependent plasticity.Neuropsychopharmacology (2006) 31, 2758–2766. doi:10.1038/sj.npp.1301122; published online 14 June 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
28. A NEW UNSTABLE HEMOGLOBIN VARIANT WITH LOW OXYGEN AFFINITY: Hb ILMENAU [β41(C7)Phe→Cys].
- Author
-
Préhu, Claude, Behnken, Lütje J., Neumann, Rüdiger, Riou, Jean, Kister, Jean, Kiger, Laurent, Promé, Danielle, Arndt, Torsten, Semmelroggen, Britta, Schmidt, Margot, Galactéros, Frédéric, and Wajcman, Henri
- Subjects
- *
HEMOGLOBIN polymorphisms , *HEMOGLOBINS - Abstract
Examines an unstable hemoglobin variant with low oxygen affinity. Electrophoretic analysis of the hemolysate; Elution pattern of the trypic digest of the aminoethylated mutated chain; Oxygen binding properties.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.